151 related articles for article (PubMed ID: 16617317)
1. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma.
Abe M; Kido S; Hiasa M; Nakano A; Oda A; Amou H; Matsumoto T
Leukemia; 2006 Jul; 20(7):1313-5. PubMed ID: 16617317
[No Abstract] [Full Text] [Related]
2. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
[TBL] [Abstract][Full Text] [Related]
3. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
Yaccoby S; Pennisi A; Li X; Dillon SR; Zhan F; Barlogie B; Shaughnessy JD
Leukemia; 2008 Feb; 22(2):406-13. PubMed ID: 18046446
[TBL] [Abstract][Full Text] [Related]
4. BAFF, APRIL and their receptors: structure, function and signaling.
Bossen C; Schneider P
Semin Immunol; 2006 Oct; 18(5):263-75. PubMed ID: 16914324
[TBL] [Abstract][Full Text] [Related]
5. Travelling with the BAFF/BLyS family: are we there yet?
Mackay F; Cancro MP
Semin Immunol; 2006 Oct; 18(5):261-2. PubMed ID: 16905331
[No Abstract] [Full Text] [Related]
6. TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice.
Moon EY; Ryu SK
Exp Mol Med; 2007 Jun; 39(3):343-52. PubMed ID: 17603288
[TBL] [Abstract][Full Text] [Related]
7. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development.
Alexaki VI; Notas G; Pelekanou V; Kampa M; Valkanou M; Theodoropoulos P; Stathopoulos EN; Tsapis A; Castanas E
J Immunol; 2009 Nov; 183(9):5948-56. PubMed ID: 19828625
[TBL] [Abstract][Full Text] [Related]
8. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase.
Zonca M; Mancheño-Corvo P; DelaRosa O; Mañes S; Büscher D; Lombardo E; Planelles L
Tissue Eng Part A; 2012 Apr; 18(7-8):852-9. PubMed ID: 22059379
[TBL] [Abstract][Full Text] [Related]
9. APRIL is overexpressed in cancer: link with tumor progression.
Moreaux J; Veyrune JL; De Vos J; Klein B
BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
[TBL] [Abstract][Full Text] [Related]
10. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.
Moreaux J; Cremer FW; Reme T; Raab M; Mahtouk K; Kaukel P; Pantesco V; De Vos J; Jourdan E; Jauch A; Legouffe E; Moos M; Fiol G; Goldschmidt H; Rossi JF; Hose D; Klein B
Blood; 2005 Aug; 106(3):1021-30. PubMed ID: 15827134
[TBL] [Abstract][Full Text] [Related]
11. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
12. TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.
Vosters JL; Roescher N; Illei GG; Chiorini JA; Tak PP
Oral Dis; 2012 May; 18(4):365-74. PubMed ID: 22212434
[TBL] [Abstract][Full Text] [Related]
13. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
Hengeveld PJ; Kersten MJ
Blood Cancer J; 2015 Feb; 5(2):e282. PubMed ID: 25723853
[TBL] [Abstract][Full Text] [Related]
14. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties.
Mackay F; Schneider P
Cytokine Growth Factor Rev; 2008; 19(3-4):263-76. PubMed ID: 18514565
[TBL] [Abstract][Full Text] [Related]
15. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
Endo T; Nishio M; Enzler T; Cottam HB; Fukuda T; James DF; Karin M; Kipps TJ
Blood; 2007 Jan; 109(2):703-10. PubMed ID: 16973958
[TBL] [Abstract][Full Text] [Related]
16. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
17. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta.
Langat DL; Wheaton DA; Platt JS; Sifers T; Hunt JS
Am J Pathol; 2008 May; 172(5):1303-11. PubMed ID: 18403603
[TBL] [Abstract][Full Text] [Related]
19. BLyS and B cell homeostasis.
Woodland RT; Schmidt MR; Thompson CB
Semin Immunol; 2006 Oct; 18(5):318-26. PubMed ID: 16931037
[TBL] [Abstract][Full Text] [Related]
20. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
Shivakumar L; Ansell S
Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
